Latest Breaking News On - உச்சிமாநாடு மருத்துவ ஆராய்ச்சி - Page 1 : comparemela.com
PathAI and Summit Clinical Research Launch a Comprehensive NASH Clinical Trial Services Solution to Optimize Trial Success
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Summit Clinical Research, PathAI partner on clinical trial services for NASH treatments
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Share this article
FORT LAUDERDALE, Fla., Feb. 17, 2021 /PRNewswire/
ChronWell, Inc., a digital health and technology-enabled remote care management company, today announced that Stephen Harrison, MD, FACP, FAASLD, has been added to the company s Board of Advisors. I am excited about the prospect of working with the ChronWell team to further it s important work in using data and digital tools to help patients and practices together achieve better outcomes, said Dr. Harrison. With ChronWell s deep experience in harnessing clinical data, and scientific approach, I m anticipating great strides in digital healthcare in a variety of specialties, beginning with gastroenterology and liver disease.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
February 12, 2021 GMT
LYON, France (BUSINESS WIRE) Feb 12, 2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update.
ADVERTISEMENT
“Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo
Metacrine Reports Positive Results from Phase 1 Trial of MET642
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease. Findings show that treatment with MET642 was safe and generally well-tolerated and demonstrated a sustained pharmacokinetic (PK) profile and robust FXR target engagement after 14 days of daily oral dosing in healthy volunteers.
vimarsana © 2020. All Rights Reserved.